financetom
Business
financetom
/
Business
/
India's Eruditus raises $150 mln in TPG-led funding round
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India's Eruditus raises $150 mln in TPG-led funding round
Oct 17, 2024 5:56 PM

BENGALURU, Oct 18 (Reuters) - Indian educational technology company Eruditus has raised

$150 million in a new funding round led by private equity firm TPG, at a time when the

funding environment for edtech companies has been subdued.

Eruditus' Series F round, which also saw the participation of existing backers Softbank

, Leeds Illuminate, Accel, CPP Investments and Chan Zuckerberg Initiative, was raised at

a valuation of $3 billion.

Co-founder and CEO Ashwin Damera told Reuters the focus will be on building AI products for

teaching experiences, expanding focus to sell courses to enterprises and to double down on the

Indian market, especially as Eruditus considers going public in India in the future.

"Today, India for us is about 28% of our overall business, and over the next five years, I

would love to see India be at least 50% of what we do," Damera said.

However, the Indian edtech sector is in a tough spot, with companies having raised only $419

million this year, a far cry from the $5.37 billion raised in 2021, according to information

provider Tracxn. Edtech firm Physics Wallah raised $210 million last month.

Post fundraise, Eruditus will start the process of shifting its domicile to India from

Singapore, Damera said.

Eruditus is one of several startups looking to change its legal address to India due to

better public listing prospects.

Companies in the country have raised over $9 billion through IPOs this year, higher than the

$7.42 billion raised in 2023, according to data compiled by LSEG.

Damera, however, did not offer a timeline for a listing.

"We have to ask ourselves what's the right time for us as a company (for an IPO), we just

have a new investor. We'll have a discussion, we're not dying to go public right away. We still

have a lot of things to build and do," he said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved